
Quick Take
Rubius Therapeutics (RUBY) intends to raise $200 million from the sale of its common stock in a U.S. IPO, according to an SEC filing.
The firm is a very early stage biopharma developing a diverse pipeline of treatments using red blood cells as the primary delivery mechanism.
RUBY management is asking IPO investors to pay a valuation of at least 4x the recent normal range for biopharma firm IPOs. In addition, there are no disclosed collaboration partners.

